Actively Recruiting
A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult Volunteers
Led by AlphaMol Science Ltd. (Shanghai) · Updated on 2025-12-12
60
Participants Needed
1
Research Sites
44 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Alpha-0261 tablets after single oral administration in healthy adult volunteers.
CONDITIONS
Official Title
A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult Volunteers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 55 years, male or female
- Weight at least 50 kg for males or 45 kg for females
- Body mass index (BMI) between 19 and 28 kg/m2
- In generally good health
You will not qualify if you...
- History of severe allergic reaction or anaphylaxis
- Any condition that might jeopardize safety or compliance with the protocol
- Clinically significant abnormalities in laboratory results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bishan Hospital of Chongqing
Chongqing, China
Actively Recruiting
Research Team
L
Lei Wan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here